Abstract |
We examined the adjunctive effect of a novel factor Xa inhibitor, YM-60828, on vessel patency and blood loss from the operation site after successful thrombolysis with a modified tissue-type plasminogen activator ( moPA) in an electrically-induced carotid artery thrombosis model in rats. Five minutes after the induction of occlusive thrombus, a test drug ( YM-60828, argatroban, heparin or saline) was administered by i.v. bolus injection followed by continuous infusion. Thrombolysis was induced with moPA by i.v. bolus injection at a dose of 650,000 IU/ kg. YM-60828 at 1 mg/kg i.v. followed by 3 mg/kg/h significantly prevented reocclusion, increased the duration of patency, and improved vessel patency after successful thrombolysis without any significant increase in blood loss from the operation site. Argatroban at 1 mg/kg i.v. followed by 3 mg/kg/h and heparin at 300 U/kg i.v. followed by 150 U/kg/h also significantly improved these parameters, but were accompanied by a significant increase in blood loss. These results suggest that the factor Xa inhibitor YM-60828 may be a potent and useful adjunctive agent with a lower risk of bleeding complications than argatroban and heparin in thrombolytic therapy.
|
Authors | T Kawasaki, K Sato, F Hirayama, H Koshio, Y Taniuchi, Y Matsumoto |
Journal | Thrombosis and haemostasis
(Thromb Haemost)
Vol. 79
Issue 4
Pg. 859-64
(Apr 1998)
ISSN: 0340-6245 [Print] Germany |
PMID | 9569205
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anticoagulants
- Naphthalenes
- Pipecolic Acids
- Piperidines
- Serine Proteinase Inhibitors
- Sulfonamides
- YM 60828
- Heparin
- Arginine
- Tissue Plasminogen Activator
- argatroban
|
Topics |
- Animals
- Anticoagulants
(pharmacology, therapeutic use, toxicity)
- Arginine
(analogs & derivatives)
- Blood Loss, Surgical
(prevention & control)
- Carotid Arteries
(drug effects, ultrastructure)
- Carotid Artery Thrombosis
(drug therapy, pathology)
- Drug Evaluation, Preclinical
- Hemorrhage
(chemically induced)
- Heparin
(pharmacology, therapeutic use, toxicity)
- Male
- Naphthalenes
(pharmacology, therapeutic use, toxicity)
- Pipecolic Acids
(pharmacology, therapeutic use, toxicity)
- Piperidines
(pharmacology, therapeutic use, toxicity)
- Rats
- Recurrence
- Reperfusion
- Serine Proteinase Inhibitors
(pharmacology, therapeutic use, toxicity)
- Sulfonamides
- Thrombolytic Therapy
- Time Factors
- Tissue Plasminogen Activator
(pharmacology, therapeutic use, toxicity)
|